Menu
A California think tank and drug industry advocates penned new op-eds warning against the possible 340B impacts of President Donald Trump's Medicaid drug pricing proposal.

Drug Industry Advocates Say 340B Providers Would be Unintended Beneficiaries in Effort to Kill Trump Proposed Medicaid Pricing Proposal

Shannon Young, Associate Editor/Senior Writer 340B Report Views
A California think tank, and an influential drug industry trade group that funds it, are raising concerns that President Donald [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Contract Pharmacy Lawsuit Roundup: Key Briefs Filed in Nebraska, South Dakota and 5th Circuit

In Win for Hospitals, Stricter 340B Bill Dies in Colorado One Day After Legislature Passes Provider-Backed Alternative

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Quick verification required before signup

Site Footer Live